诺和锐30强化与诺和灵30R治疗2型糖尿病的临床疗效对比分析(1)
[摘要] 目的 分析并且探讨诺和灵30R与诺和锐30强化医治2型糖尿疾病的临床效果。 方法 将该院2012年—2014年期间诊治的72例2型糖尿疾病的患者进行研究，并将他们分成研究组与对照组，每组36例。研究组选择诺和锐30强化对患者进行医治，对照组则选择诺和灵30R进行医治。观察并对比两组医治后的HbA1c、FBG和2hPBG的改变，并对血糖达标的时间与发生低血糖的几率进行计算。结果 医治后，研究组不仅HbA1c、FBG与2 hPBG都比对照组低，且血糖达标的时间与发生低血糖的几率也比对照组少，组间差异有统计学意义(P<0.05)。结论 选择诺和锐30强化对于2型糖尿疾病患者的医治效果要明显好于诺和灵30R，值得在临床中推广及应用。
[关键词] 糖尿病；诺和灵；诺和锐；疗效
[中图分类号] R587 [文献标识码] A [文章编号] 1672-4062(2016)03(b)-0018-03
[Abstract] Objective To analyze and probe into the clinical effects of？the novomix30R and novolin 30R in treatment of type 2 diabetes mellitus. Methods 72 patients with type 2 diabetes mellitus and who accepted treatments in our hospital from 2012 to 2014 were taken as the research objects， and these patients were randomly divided into the control group and the study group， with 36 patients in each group. In the study group， they were treated with thenovomix30R while in the control group， they were treated with the novolin 30R. Then， the changes of HbA1c， FBG and 2 hPBG after treatment of two groups were observed and compared and the the time to reach the standard of blood sugar and the probability of occurrence of hypoglycemia were calculated. Results Outcome After treatment， the study group not only the HbA1c， FBG and 2 hPBG were lower than those in the control group，but also the time of blood glucose and the incidence of hypoglycemia were less than those in the control group， and the difference had statistically significant between the groups(P<0.05). Conclusion The effects ofthe novomix30Rin treatment of patients with type 2 diabetes mellitus are significantly better than the novolin 30R， which should be promoted and applied.
[Key words] Diabetes mellitus； Novomix； Novolin； Clinical effect
糖尿疾病是一种慢性的非传染性病症，我国患有糖尿疾病的患者已经超出了3千万，当中大约有90%左右的糖尿疾病患者为患有2型糖尿疾病的患者[1]。需给予他们监测良好的措施与有效医治的方法才能将血糖良好控制[2]。该文对该院2012年—2014年期间收治的72例2型糖尿疾病的患者进行分析和研究，并对其中的36例患者选择了诺和锐30强化的医治措施，取得了较为满意的效果，现报道如下。
1 资料与方法
1.1 一般资料
此次72例患者均为该院2012年—2014年期间收治，将他们分成研究组与对照组，每组36例，该次所有患者均与WHO中2型糖尿疾病的诊断标准相符。研究组患者中，男性20例，女性16例，年龄32～73岁，平均(55.82±7.94)岁，病程1～14年，平均(7.12±2.13)年；对照组患者中，男性22例，女性14例，年龄30～70岁，平均(54.21±7.33)岁，病程2～13年，平均(6.89±1.89)年。排除标准：①有糖尿疾病严重并发症者；②心、肾与肝功能不全者；③有关药品存在过敏者。两组患者在普通资料与病程等方面上相对比差异无统计学意义(P>0.05)，有可比性。
1.2 方法
研究组选择诺和锐30(生产厂家：丹麦诺和诺德公司；国药准字：J20100037)，300 U×3 mL×1支/盒，需要在3餐以前即可在皮下进行注射，初始计量是0.4 U/(kg·d)。对照组选择诺和灵30R(生产厂家：诺和诺德(中国)制药有限公司；国药准字：J20100088)，300 U×3 mL×1支/盒，在3餐以前的30 min进行注射，初始计量同样为0.4 U/(kg·d)。需要对两组患者血糖进行严密的监测，按照血糖发生的改变对用药剂量进行调整。血糖控制的目标为：患者FPG(空腹血糖)在6.0 mmol/L，2hPBG(饭后2 h的血糖)在10.0 mmol/L以下，HbA1c(糖化的血红蛋白)在7.0%以下。, 百拇医药(王德江)
[关键词] 糖尿病；诺和灵；诺和锐；疗效
[中图分类号] R587 [文献标识码] A [文章编号] 1672-4062(2016)03(b)-0018-03
[Abstract] Objective To analyze and probe into the clinical effects of？the novomix30R and novolin 30R in treatment of type 2 diabetes mellitus. Methods 72 patients with type 2 diabetes mellitus and who accepted treatments in our hospital from 2012 to 2014 were taken as the research objects， and these patients were randomly divided into the control group and the study group， with 36 patients in each group. In the study group， they were treated with thenovomix30R while in the control group， they were treated with the novolin 30R. Then， the changes of HbA1c， FBG and 2 hPBG after treatment of two groups were observed and compared and the the time to reach the standard of blood sugar and the probability of occurrence of hypoglycemia were calculated. Results Outcome After treatment， the study group not only the HbA1c， FBG and 2 hPBG were lower than those in the control group，but also the time of blood glucose and the incidence of hypoglycemia were less than those in the control group， and the difference had statistically significant between the groups(P<0.05). Conclusion The effects ofthe novomix30Rin treatment of patients with type 2 diabetes mellitus are significantly better than the novolin 30R， which should be promoted and applied.
[Key words] Diabetes mellitus； Novomix； Novolin； Clinical effect
糖尿疾病是一种慢性的非传染性病症，我国患有糖尿疾病的患者已经超出了3千万，当中大约有90%左右的糖尿疾病患者为患有2型糖尿疾病的患者[1]。需给予他们监测良好的措施与有效医治的方法才能将血糖良好控制[2]。该文对该院2012年—2014年期间收治的72例2型糖尿疾病的患者进行分析和研究，并对其中的36例患者选择了诺和锐30强化的医治措施，取得了较为满意的效果，现报道如下。
1 资料与方法
1.1 一般资料
此次72例患者均为该院2012年—2014年期间收治，将他们分成研究组与对照组，每组36例，该次所有患者均与WHO中2型糖尿疾病的诊断标准相符。研究组患者中，男性20例，女性16例，年龄32～73岁，平均(55.82±7.94)岁，病程1～14年，平均(7.12±2.13)年；对照组患者中，男性22例，女性14例，年龄30～70岁，平均(54.21±7.33)岁，病程2～13年，平均(6.89±1.89)年。排除标准：①有糖尿疾病严重并发症者；②心、肾与肝功能不全者；③有关药品存在过敏者。两组患者在普通资料与病程等方面上相对比差异无统计学意义(P>0.05)，有可比性。
1.2 方法
研究组选择诺和锐30(生产厂家：丹麦诺和诺德公司；国药准字：J20100037)，300 U×3 mL×1支/盒，需要在3餐以前即可在皮下进行注射，初始计量是0.4 U/(kg·d)。对照组选择诺和灵30R(生产厂家：诺和诺德(中国)制药有限公司；国药准字：J20100088)，300 U×3 mL×1支/盒，在3餐以前的30 min进行注射，初始计量同样为0.4 U/(kg·d)。需要对两组患者血糖进行严密的监测，按照血糖发生的改变对用药剂量进行调整。血糖控制的目标为：患者FPG(空腹血糖)在6.0 mmol/L，2hPBG(饭后2 h的血糖)在10.0 mmol/L以下，HbA1c(糖化的血红蛋白)在7.0%以下。, 百拇医药(王德江)